Scientists discover potential new target for prostate cancer treatment

February 13, 2011

(PhysOrg.com) -- Scientists at the University of Glasgow have discovered how a protein present in prostate cancer cells drives growth of the disease.

Professor Hing Leung, of the University’s College of Medical, Veterinary and Life Sciences, said the finding could lead to the development of better treatment for patients in future.

is the most common cancer diagnosed in men in the UK. Each year 36,000 men are diagnosed with the disease - 2,500 of these are in Scotland.

The study, reported in the new edition of the British Journal of Cancer (published 15 February) has been described by researchers and cancer charities as “extremely exciting”.

ERK5 is a within a cell and works as part of the ‘information highway’ to control the growth and development of cancer.

According to Prof Leung’s study, ERK5 is present in abnormally high levels of prostate cancer, including invasive cancer which has spread to other parts of the body. It is also present in relapsed cancer following previous hormone therapy.

Prof Leung explains: “When the effects of ERK5 are reduced in the laboratory, we observed less ‘invasion’ by the cancer cells. This supports the idea that medicine or drugs blocking ERK5 might be useful in the clinic.

“In addition, when we increased the amount of ERK5 in , again in the laboratory, they developed more cancer out with the prostate. This makes ERK5 a very exciting molecule to develop new treatment on.”

He continued: “The fact is prostate cancer which shows metastatic spread or that has relapsed after previous hormone treatment does not respond well to the current treatment available to patients.

“The possibility of a new target for better cancer treatment is very encouraging. Indeed ERK5 may be important, too, in other cancer types including breast cancer.”

The research was part funded by Cancer Research UK (CRUK), the Beatson Institute and the Prostate Cancer Charity.

Dr Helen Rippon, head of research management at The Prostate Cancer Charity, added: “This new research is an important step forward in helping us to understand how ERK5 is involved in driving the growth of prostate cancer, particularly the more aggressive forms of the disease.

“We look forward to following the results of these follow up studies with great interest.”

More information: “ERK5 signalling in Prostate cancer promotes an invasive phenotype” is currently on AOP - advance online publication. www.nature.com/bjc/journal/vao … t/full/6606062a.html

Related Stories

Recommended for you

Stem cell therapy attacks cancer by targeting unique tissue stiffness

July 26, 2017
A stem cell-based method created by University of California, Irvine scientists can selectively target and kill cancerous tissue while preventing some of the toxic side effects of chemotherapy by treating the disease in a ...

Understanding cell segregation mechanisms that help prevent cancer spread

July 26, 2017
Scientists have uncovered how cells are kept in the right place as the body develops, which may shed light on what causes invasive cancer cells to migrate.

Study uncovers potential 'silver bullet' for preventing and treating colon cancer

July 26, 2017
In preclinical experiments, researchers at VCU Massey Cancer Center have uncovered a new way in which colon cancer develops, as well as a potential "silver bullet" for preventing and treating it. The findings may extend to ...

Compound shows promise in treating melanoma

July 26, 2017
While past attempts to treat melanoma failed to meet expectations, an international team of researchers are hopeful that a compound they tested on both mice and on human cells in a petri dish takes a positive step toward ...

Study may explain failure of retinoic acid trials against breast cancer

July 25, 2017
Estrogen-positive breast cancers are often treated with anti-estrogen therapies. But about half of these cancers contain a subpopulation of cells marked by the protein cytokeratin 5 (CK5), which resists treatment—and breast ...

Breaking the genetic resistance of lung cancer and melanoma

July 25, 2017
Researchers from Monash University and the Memorial Sloan Kettering Cancer Center (MSKCC, New York) have discovered why some cancers – particularly lung cancer and melanoma – are able to quickly develop deadly resistance ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.